journal
Journals Dermatology : International Jo...

Dermatology : International Journal for Clinical and Investigative Dermatology

https://read.qxmd.com/read/38934138/value-based-healthcare-a-primer-for-the-dermatologist
#21
REVIEW
Deepak M W Balak, Elfie Deprez, Niels Timo Hilhorst, Isabelle Hoorens, Jan Gutermuth, Willem Jan W Bos, Jo Lambert
BACKGROUND: Value-based healthcare (VBHC) is an increasingly employed strategy to transform healthcare organizations into economically sustainable systems that deliver high-value care. In dermatology, the need for VBHC is evident as chronic skin diseases require long-term, often expensive treatments. This narrative review aims to introduce dermatologists to the principles and implementation of VBHC. SUMMARY: VBHC emphasizes maximizing outcomes that are directly relevant to patients...
June 27, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38901417/re-regarding-the-predictors-of-recurrence-and-progression-in-poorly-differentiated-cutaneous-squamous-cell-carcinomas
#22
LETTER
Gabriele Roccuzzo, Rebecca Senetta, Simone Ribero
No abstract text is available yet for this article.
June 20, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38897192/post-excision-soft-x-ray-radiotherapy-for-keloids-experience-in-a-tertiary-referral-center
#23
JOURNAL ARTICLE
Egle Ramelyte, Michèle Welti, Fabian Gardin, Julia-Tatjana Maul, Reinhard Dummer, Laurence Imhof
INTRODUCTION: Keloid is an abnormal proliferation of scar tissue that grows beyond the original margins of the injury. Even after complete resection, recurrences are common and pose a poorly understood challenge in dermatology. There is lack of large prospective clinical trials, thus treatment recommendations are based on retrospective analyses and small cohort studies. Superficial radiotherapy is recommended in recurrent keloids; however, the successful treatment rates vary greatly. The aim of this study is to evaluate the keloid recurrence rate after post excision soft x-ray radiotherapy and the associated factors...
June 19, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38889692/evaluation-of-the-impact-of-night-shift-work-on-disease-severity-in-psoriatic-patients-a-case-control-study-with-clinical-hormonal-and-immunological-evaluation
#24
Giacomo Caldarola, Eleonora De Luca, Angelina Barini, Umberto Basile, Valeria Carnazzo, Andrea Chiricozzi, Barbara Tolusso, Elisa Gremese, Lucia Di Nardo, Ketty Peris, Clara De Simone
INTRODUCTION: Night shift work disrupts circadian rhythms and has been associated with immune system alterations and various health conditions. However, there is limited data regarding its impact on psoriasis. The aim of our study was to compare psoriasis severity and the hormonal and immunological profile in patients with a night shift work to those with a daytime occupation. METHODS: In this case-control study, we enrolled psoriatic patients aged >18 years engaged in night shift work and a control group of psoriatic patients with a daytime occupation...
June 18, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38857576/challenges-in-psoriasis-research-a-systematic-review-of-preclinical-models
#25
JOURNAL ARTICLE
Ana Ubago-Rodríguez, María I Quiñones-Vico, Manuel Sánchez-Díaz, Raquel Sanabria-de la Torre, Álvaro Sierra-Sánchez, Trinidad Montero-Vílchez, Ana Fernández-González, Salvador Arias-Santiago
INTRODUCTION: Psoriasis is a chronic inflammatory skin disease with variable clinical presentation, multifactorial etiology and an immunogenetic basis. Several studies demonstrate that it results from a dysregulated interaction between skin keratinocytes, immune cells and the environment that leads to a persistent inflammatory process modulated by cytokines and T cells.The development of new treatment options requires increased understanding of pathogenesis. However, the successful implementation of effective drugs requires well-characterized and highly available preclinical models that allow researchers to quickly and reproducibly determine their safety and efficacy...
June 10, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38852575/the-typical-nail-lichen-planus-severity-index-tnlpsi-%C3%AF-an-outcome-instrument-for-typical-nail-lichen-planus
#26
JOURNAL ARTICLE
Juan He, Tengyu Weng, Wei Zhang, Anqi Li, Xianfu Meng, Wenwei Zhu, Jia Bai, Yonghong Hao, Yi Yang, Chengxin Li
INTRODUCTION: Despite numerous treatment options for Nail lichen planus (NLP), a validated method for measuring the severity of NLP and therapeutic response in clinical trials is absent. To develop and validate a measurement instrument (tNLPSI - typical nail lichen planus severity index) for typical nail lichen planus that could be used in clinical trials. METHODS: 48 patients with typical NLP diagnosed pathologically and 5 dermatologists participated. The physicians were trained to use the tNLPSI activity scale and Physician's Global Assessment (PGA)...
June 8, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38810613/drug-induced-and-malignancy-associated-neutrophilic-dermatoses-in-patients-with-hematologic-malignancies-a-single-institution-experience
#27
Mallory deCampos-Stairiker, Shannon Kody, Gabrielle Meyers, Julia Maxson, Alex Ortega-Loayza
INTRODUCTION: Neutrophilic dermatoses (NDs) often occur secondary to inflammatory conditions, medication exposure, and hematologic malignancy. While malignancy-associated NDs (MA-NDs) have been well-reported among those with hematologic cancers, little is known about drug-induced NDs (DI-NDs) within this population. The objective of this study is to compare the presentations and outcomes of patients with hematologic malignancies who developed MA-NDs and DI-NDs. METHODS: Cases of neutrophilic dermatosis (ND) occurring between 2013 and 2023 among those with hematologic malignancies were identified from the electronic medical records of our institution...
May 29, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38797158/hematological-markers-in-children-and-adults-with-atopic-dermatitis-a-retrospective-cohort-study
#28
JOURNAL ARTICLE
Sarah Weissmann, Amit Shira Babyev, Michal Gordon, Inbal Golan-Tripto, Amir Horev
Background Atopic dermatitis (AD) is a common chronic skin disease with an inflammatory pathophysiology that includes the activation of the innate and adaptive immune systems. Objectives We aimed to investigate the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), eosinophil-to-lymphocyte ratio (ELR) and eosinophil-to-neutrophil ratio (ENR) in AD patients, according to age and disease severity. Methods This is a retrospective, population-based cohort study conducted between the years 2005 and 2020, comparing hematological markers of AD patients and sex-age-ethnicity matched controls...
May 26, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38797168/efficacy-and-safety-of-dupilumab-in-chinese-elderly-patients-with-atopic-dermatitis-a-real-world-study
#29
JOURNAL ARTICLE
Yu-Qing Hu, Jian-Zhong Zhang, Yan Zhao
Introduction With the aging of the population in China, the prevalence of atopic dermatitis (AD) is high in the elderly patients. These patients usually have more comorbidities and they need more effective and safer treatments. Dupilumab is an anti-interleukin-4 (IL-4) receptor monoclonal antibody which was approved for the treatment of moderate to severe AD. Objective To investigate the efficacy and safety of dupilumab in elderly patients with moderate to severe AD. Methods A real world retrospective study was conducted...
May 24, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38772345/cutaneous-reactions-in-pediatric-patients-treated-with-mek-inhibitors-a-retrospective-single-center-study
#30
JOURNAL ARTICLE
Rivka Friedland, Mirit Glick, Iris Amitay-Laish, Helen Toledano
Introduction MEK inhibitors are in use for several indications for adults and children. Cutaneous toxicities are among the most common adverse effects. We aimed to describe the spectrum of cutaneous adverse events, its frequency and severity in a cohort of pediatric patients. Methods We reviewed all records of patients in our tertiary treatment center treated with MEK inhibitors between January 2016 and January 2023 for all indications. Results Among 33 patients, 76% reported cutaneous adverse effects. The highest prevalence was in the group of patients treated with trametinib (90%), followed by the group treated with selumetinib (50%) and the group treated with combination of trametinib and BRAF inhibitor (dabrafenib, 34%)...
May 21, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38768566/preoperative-mapping-biopsies-with-local-excision-in-the-treatment-of-extramammary-paget-disease-a-retrospective-cohort-study-systematic-review-and-individual-patient-data-analysis
#31
LETTER
Sophie Soyeon Lim, Ji Su Lee, Hyun Jeong Ju, Jung Min Bae, Seong Jin Jo, Je-Ho Mun
BACKGROUND: Surgical excision of extramammary Paget disease (EMPD) is associated with a high local recurrence rate. OBJECTIVES: This study aimed to assess the local recurrence rate of EMPD after preoperative mapping biopsy (PMB) with local excision. METHODS: This retrospective study included patients with EMPD who were treated at our dermatosurgery clinic between January 2016 through May 2022. In addition, we retrieved individual patient data of EMPD cases from articles published in PubMed, Cochrane, Embase, and Scopus to compare recurrence rates between patients with or without PMB using Cox's proportional hazard model...
May 20, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38735287/rare-med12l-variants-is-associated-with-susceptibility-to-guttate-psoriasis-in-the-han-chinese-population
#32
JOURNAL ARTICLE
Kejia Wu, Wanrong Wang, Qianhui Cheng, Duncheng Xiao, Yunxiao Li, Mengyun Chen, Xiaodong Zheng
INTRODUCTION: According to the common disease/rare variant (CDRV) hypothesis, it is important to study the role of rare variants in complex diseases. The association of rare variants with psoriasis has been demonstrated, but the association between rare variants and specific clinical subtypes of psoriasis has not been investigated. METHODS: Gene-based and gene-level meta-analyses were performed on data extracted from our previous study data sets(2,483 patients with guttate psoriasis and 8,292 patients with non-guttate psoriasis) for genotyping...
May 10, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38697027/clinical-use-of-super-bioavailable-itraconazole-for-the-management-of-dermatophytosis-consensus-statement-by-dermatologists-from-india-via-the-modified-delphi-technique
#33
JOURNAL ARTICLE
Abir Saraswat, Sunil Dogra, Manjunath Shenoy, Shyam Verma, Seetharam K, Sunil Ghate, Anil Ganjoo, Sanjeev Aurangabadkar, Anurag Tiwari, Shital Poojary, Arun Inamdar, Imran Majid, Mukesh Girdhar, Bela Shah, Sachin Varma, Ramkumar Ramamoorthy, Dhiraj Dhoot, Hanmant Barkate
INTRODUCTION: Super bioavailable itraconazole (SB ITZ) overcomes the limitations of conventional itraconazole (CITZ) such as inter-individual variability and reduced bioavailability. It has been approved for systemic mycoses in Australia and Europe as 50mg and the United States as 65mg and in India as 50mg, 65mg, 100mg, and 130mg. However, data on the ideal dose and duration of SB ITZ treatment in managing dermatophytosis is insufficient. This consensus discusses the suitability, dosage, duration of treatment, and relevance of using SB ITZ in managing dermatophytosis in different clinical scenarios...
May 2, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38679001/dermatology-life-quality-index-dlqi-in-patients-with-atopic-dermatitis-are-not-relevant-responses-relevant
#34
Anna Langenbruch, Valerie Andrees, Matthias Augustin
INTRODUCTION: According to the DLQI user manual, the patients´ answers 'not relevant' (NR) and 'not at all' (affected in this aspect of life by the skin problem) are treated equally and interpreted as no impairment in health related quality of life (HRQoL). The aim of this study was to gain more insights about 'not relevant' responders with atopic dermatitis (AD). METHODS: 3,353 patients with AD, recruited from dermatological offices and a patient organisation, were surveyed in three cross-sectional studies...
April 27, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38679004/topical-corticosteroid-phobia-among-danish-pharmacy-staff
#35
JOURNAL ARTICLE
Jakob Maarbjerg Toft-Hansen, Line Brok Nørreslet, Ida Vittrup, Jacob Pontoppidan Thyssen, Tove Agner, Yasemin Topal Yüksel
BACKGROUND: Topical corticosteroid (TCS) phobia may negatively impact treatment adherence. Currently, there are few studies exploring trust and knowledge of TCS use among pharmacy staff. OBJECTIVE: To examine TCS knowledge and possible phobia among Danish pharmacy staff. METHODS: A questionnaire, based on Topical Corticosteroid Phobia (TOPICOP©) questionnaire, was developed and rephrased to fit pharmacy staff. The questions were Likert scales and numerical rating scales (NRS) (0-10)...
April 26, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38648732/erratum
#36
(no author information available yet)
No abstract text is available yet for this article.
April 22, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38631324/quality-of-life-impact-in-patients-with-cutaneous-toxicities-caused-by-egfr-inhibitors-and-immunotherapy
#37
JOURNAL ARTICLE
Maria Mannino, Pietro Sollena, Alessandro Di Stefani, Ernesto Rossi, Ettore D'Argento, Giovanni Schinzari, Giampaolo Tortora, Ketty Peris
BACKGROUND: novel oncologic therapies, including epidermal growth factor receptor inhibitors (EGFR-Is) and immune checkpoint inhibitors (ICIs), are associated with a new spectrum of adverse reactions, with prominent cutaneous toxicities. The impact of cutaneous adverse events (cAEs) on patients' quality of life (QoL) represents an unmet clinical need. OBJECTIVES: 1) to assess whether cutaneous toxicities directed therapies are effective in reducing the QoL burden via the submission of two patient reported outcome measures (PROMs); 2) to investigate whether class of oncologic therapy, type of cAE and toxicity severity differently impact on patients' QoL...
April 17, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38621365/belgian-patients-of-the-european-registry-for-hidradenitis-suppurativa-erhs-be-data-scores-and-phenotypes-since-2015
#38
JOURNAL ARTICLE
Stephanie Heudens, Anne-Sophie Sarkis, Mathieu Daoud, Mathilde Daxhelet, Farida Benhadou, Mariano Suppa, Laura Nobile, Jalila Karama, Hassane Njimi, Jonathan M White, Veronique Del Marmol
Introduction Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease, characterized by painful and recurrent lesions in apocrine gland-bearing skin areas. It is a heterogeneous disease, which makes assessment and data collection difficult. Questionnaires with detailed items, such as the Belgian European Registry for Hidradenitis Suppurativa (ERHS-Be), are useful to study HS and its associated comorbidities. The aim of this registry is to uncover new factors associated with HS, understand HS patients' clinical profiles and efficacy of treatments...
April 15, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38599206/response-to-a-bibliometrics-of-the-treatment-of-alopecia-areata-in-the-past-twenty-years
#39
LETTER
Ambika Nohria, Deesha Desai, Kristen Lo Sicco, Jerry Shapiro
No abstract text is available yet for this article.
April 10, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38599196/efficacy-of-combinational-treatment-versus-nicotinamide-monotherapy-in-the-prevention-of-ultraviolet-radiation-induced-skin-cancer
#40
JOURNAL ARTICLE
Celina Pihl, Flemming Andersen, Peter Bjerring, Merete Haedersdal, Catharina Margrethe Lerche
INTRODUCTION: Ultraviolet radiation (UVR) is the primary risk factor for keratinocyte carcinomas (KC). Oral supplementation with nicotinamide (NAM; NAM-mono) is reported to reduce the formation of new KCs. NAM's photoprotection is mediated by enhanced DNA repair. We wanted to explore whether NAM in combination with anti-proliferative (Metformin; Met) or antioxidant (Phloroglucinol; PG) compounds could potentially enhance its photoprotective effects. METHODS: Hairless mice (C3...
April 10, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
journal
journal
30954
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.